Portfolio Design Labs LLC Purchases New Stake in Gilead Sciences, Inc. $GILD

Portfolio Design Labs LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,178 shares of the biopharmaceutical company’s stock, valued at approximately $1,286,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $15,393,785,000. Norges Bank acquired a new position in Gilead Sciences in the 4th quarter valued at about $2,617,152,000. Deutsche Bank AG acquired a new position in Gilead Sciences in the 2nd quarter valued at about $918,387,000. Boston Partners purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $398,905,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider owned 118,234 shares in the company, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 82,000 shares of company stock worth $10,837,860. Company insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Gilead Sciences Trading Down 2.8%

NASDAQ GILD opened at $143.44 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32. The firm has a 50 day simple moving average of $131.56 and a 200-day simple moving average of $136.52. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the prior year, the business earned $2.01 EPS. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GILD. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Truist Financial decreased their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Morgan Stanley reduced their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.